MA33417B1 - Compositions pharmaceutiques et formes solides - Google Patents

Compositions pharmaceutiques et formes solides

Info

Publication number
MA33417B1
MA33417B1 MA34518A MA34518A MA33417B1 MA 33417 B1 MA33417 B1 MA 33417B1 MA 34518 A MA34518 A MA 34518A MA 34518 A MA34518 A MA 34518A MA 33417 B1 MA33417 B1 MA 33417B1
Authority
MA
Morocco
Prior art keywords
yloxy
pyrimidin
hydroxymethyl
trifluoromethyl
naphthalene
Prior art date
Application number
MA34518A
Other languages
Arabic (ar)
English (en)
Inventor
Joerg Berghausen
Claire Haug
Michael Herbig
Bin Hu
Stéphane Jonat
Rajender Leleti
Josef Gottfried Meingassner
Stéphanie Monnier
Matthias Napp
Mahavir Prashad
Anton Stuetz
Ranjit Thakur
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33417B1 publication Critical patent/MA33417B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques de (3-trifluorométhyl-phényl)-amide d'acide 6-(6-hydroxyméthyl-pyrimidin-4-yloxy)-naphthalène-1-carboxylique, l'utilisation de (3-trifluorométhyl-phényl)-amide d'acide 6-(6-hydroxyméthyl-pyrimidin-4-yloxy)-naphthalène-1-carboxylique et des compositions de (3-trifluorométhyl-phényl)-amide d'acide 6-(6-hydroxyméthyl-pyrimidin-4-yloxy)-naphthalène-1-carboxylique dans des applications thérapeutiques, en particulier des indications associées à une mauvaise régulation/surexpression de VEGF, une (néo)vascularisation et une angiogenèse dirigée par VEGF et des procédés de fabrication de ces compositions. L'invention concerne en outre des formes spécifiques de (3-trifluorométhyl-phényl)-amide d'acide 6-(6-hydroxyméthyl-pyrimidin-4-yloxy)-naphthalène-1-carboxylique et la fabrication et l'utilisation de ces formes. La présente invention concerne également un nouveau procédé pour produire du (3-trifluorométhyl-phényl)-amide d'acide 6-(6-hydroxyméthyl-pyrimidin-4-yloxy)-naphthalène-1-carboxylique.
MA34518A 2009-07-06 2010-07-05 Compositions pharmaceutiques et formes solides MA33417B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22326909P 2009-07-06 2009-07-06
PCT/EP2010/059553 WO2011003858A2 (fr) 2009-07-06 2010-07-05 Compositions pharmaceutiques et formes solides

Publications (1)

Publication Number Publication Date
MA33417B1 true MA33417B1 (fr) 2012-07-03

Family

ID=42686504

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34518A MA33417B1 (fr) 2009-07-06 2010-07-05 Compositions pharmaceutiques et formes solides

Country Status (20)

Country Link
US (1) US20110112121A1 (fr)
EP (1) EP2451458A2 (fr)
JP (1) JP2012532183A (fr)
KR (1) KR20120041745A (fr)
CN (1) CN102470134A (fr)
AR (1) AR077549A1 (fr)
AU (1) AU2010270361A1 (fr)
BR (1) BR112012000383A2 (fr)
CA (1) CA2767440A1 (fr)
CO (1) CO6480987A2 (fr)
EA (1) EA201200095A1 (fr)
EC (1) ECSP12011578A (fr)
IL (1) IL217329A0 (fr)
MA (1) MA33417B1 (fr)
MX (1) MX2012000391A (fr)
SG (1) SG176955A1 (fr)
TN (1) TN2011000653A1 (fr)
TW (1) TW201113258A (fr)
WO (1) WO2011003858A2 (fr)
ZA (1) ZA201200079B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2183273T (pt) 2007-08-17 2017-05-22 Novartis Ag Depsipéptidos cíclicos
US8614289B2 (en) 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8680054B2 (en) * 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
CN104860885B (zh) 2014-02-24 2017-11-17 中国科学院上海药物研究所 萘酰胺类化合物、其制备方法和用途
SE1751461A1 (en) 2017-11-28 2019-05-29 Ascilion Ab Method of detecting an exogenous agent in interstitial fluid
WO2019126270A1 (fr) * 2017-12-20 2019-06-27 Sienna Biopharmaceuticals, Inc. Formulations d'administration dermique de conjugués polymères de composés indolocarbazole à exposition réduite
WO2026006488A1 (fr) * 2024-06-26 2026-01-02 Antinous Technology Company Limited Inhibiteurs d'angiogenèse et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355657B1 (en) * 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
HK1054393B (en) * 2000-09-20 2009-08-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
AU9598601A (en) * 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
SI1478358T1 (sl) * 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
WO2004103159A2 (fr) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methodes de modulation de l'endometre
GEP20084439B (en) * 2004-01-23 2008-07-25 Amgen Inc Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
GB0518671D0 (en) * 2005-09-13 2005-10-19 Novartis Ag Organic compounds
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
KR101487027B1 (ko) * 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
WO2008031835A2 (fr) * 2006-09-13 2008-03-20 Novartis Ag Méthode de traitement de maladies auto-immunes à l'aide d'inhibiteurs de la voie vegf

Also Published As

Publication number Publication date
CN102470134A (zh) 2012-05-23
TW201113258A (en) 2011-04-16
ZA201200079B (en) 2012-09-26
TN2011000653A1 (en) 2013-05-24
CO6480987A2 (es) 2012-07-16
IL217329A0 (en) 2012-02-29
AU2010270361A1 (en) 2012-01-19
EP2451458A2 (fr) 2012-05-16
AR077549A1 (es) 2011-09-07
JP2012532183A (ja) 2012-12-13
MX2012000391A (es) 2012-02-28
WO2011003858A3 (fr) 2011-03-03
US20110112121A1 (en) 2011-05-12
ECSP12011578A (es) 2012-02-29
WO2011003858A2 (fr) 2011-01-13
CA2767440A1 (fr) 2011-01-13
KR20120041745A (ko) 2012-05-02
EA201200095A1 (ru) 2012-08-30
BR112012000383A2 (pt) 2016-03-29
SG176955A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
MA33417B1 (fr) Compositions pharmaceutiques et formes solides
ATE531711T1 (de) Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate
EA201170251A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
MA38071B1 (fr) Formes cristallines d'un inhibiteur de facteur xia
EP2351708A4 (fr) Procédé pour la fabrication d'un oxyde
FR2941817B1 (fr) Procede pour la preparation d'une composition d'electrode
MA32175B1 (fr) Oxadiazoanthracènes pour le traitement du diabète
EP2294045A4 (fr) Procédé pour la fabrication d'acide glycolique
EP2336347A4 (fr) Microorganisme apte à produire un acide aminé l et procédé pour la fabrication d'un acide aminé l
MA34926B1 (fr) Composition effervescente sous forme solide utilisable dans des applications vaginales pour le traitement d'infections vaginales
MX2013003034A (es) Lactamas piperidinilo-substituidas como moduladores de gpr119.
EP2380850A4 (fr) Montmorillonite de sodium modifiée, procédé d'élaboration et utilisations correspondants
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
PH12012502255A1 (en) Piperidinyl-substituted lactams as gpr119 modulators
EP2571876A4 (fr) Composés hétérocycliques substitués à sept chaînons en tant qu'inhibiteurs de la dipeptidyl-peptidase iv pour le traitement du diabète
MA30466B1 (fr) Nouvelle forme d'administration du racecadotril
UA112527C2 (uk) Комбінації, що містять атипові антипсихотичні засоби та агоністи taar1
MX2010008583A (es) Novedosos formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)- 5-ter-butil-pirazol-1-il]benzoico.
FR2925068B1 (fr) Procedes de production d'acide succinique
MX2012002597A (es) Nuevos inhibidores de la lipasa sensible a las hormonas (hsl) utiles para el tratamiento de la diabetes.
EA201071183A1 (ru) Безводная кристаллическая форма малеата орвепитанта
EP2380851A4 (fr) Procédé de production d'une solution d'oxyde de zirconium stabilisée par de l'oxyde d'yttrium
MA34645B1 (fr) Nouvelles formes cristallines
CY1117790T1 (el) Ενωσεις αναστολεα 11-βητα-υδροξυστεροειδους αφυδρογονασης τυπου 1